Free previewYou're reading the free part of this topic. The rest is included with Clinical.See what's included
Laser trabeculoplasty
Glaucoma
Key Points
- •The LiGHT trial established SLT as a first-line treatment for OAG/OHT: 74% of SLT-first patients needed no drops at 3 years, with non-inferior disease control (some secondary outcomes favouring SLT); superior outcomes confirmed at 6 years.
- •SLT uses selective photothermolysis (532 nm, 3 ns pulse) targeting melanin in TM cells without structural damage - unlike ALT, SLT is repeatable.
- •IOP reduction of 20–30% (equivalent to one topical medication) with peak effect at 4–8 weeks post-treatment.
- •The champagne bubble at the TM surface is the optimal SLT endpoint - reduce energy if excessive bubble or pigment scatter occurs.
- •SLT effect wanes over 1–5 years; repeat SLT is successful in 60–70% of initial responders.
Free preview ends here
Keep reading Laser trabeculoplasty
17 more sections are included with the Clinical plan.
- Definition
- Epidemiology
- Aetiology and causes
- Pathogenesis
- Classification
- Risk factors and associations